EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors

Silvia Linari, Lisa Pieri, Raffaella Pasquino, Eleonora Piellucci, Monica Attanasio, Francesca Salvianti, Giancarlo Castaman

Bleeding, Thrombosis and Vascular Biology · 11.05.2026 · 5 (2)

DOI: 10.4081/btvb.2026.467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 11.05.2026. Verfasst von Silvia Linari und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: concizumab is an anti-tissue factor inhibitor monoclonal antibody designed as a once-daily subcutaneous prophylactic treatment for all hemophilia patients. The efficacy and safety of concizumab have been documented in the Explorer research program. Objectives: we describe the management and clinical outcomes of 3 subjects treated with concizumab in the phase 3 Explorer 7 trial, in which patients with hemophilia A/B with inhibitors (HAPwI/HBPwI) were enrolled. Methods: in 3 subjects (1 HAPwI and 2 HBPwI) followed in our Centre and enrolled in Explorer 7 trial the following data were collected: diagnosis, age at switch to concizumab, pre-switch antihemorrhagic treatment, venous access, joint involvement, bleeding events in the 6 months before switch, comorbidity, medications, quality of life (QoL), physical activity, date of switch and following bleeding events, treatment with recombinant activated factor VII (rFVIIa), surgery, QoL, physical activity. Results: during the 5 years following the switch to concizumab all the patients had a drastic reduction in bleeding events and therefore of treatment with rFVIIa. A significant improvement in QoL, both in relation to pain reduction, movement ability and autonomy from caregivers, was achieved. No side effects were observed, and the management of 1 major and 14 minor surgeries did not present any bleeding or thrombotic complications. Conclusions: concizumab represents a unique opportunity for HBPwI, but it may be of extreme value also for HAPwI. In our cases concizumab demonstrates and confirms clinical efficacy, positive impact on QoL and safety even in surgical settings.

Zitieren

APA

Linari, S., Pieri, L., Pasquino, R., Piellucci, E., Attanasio, M., Salvianti, F., & Castaman, G. (2026). Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors. Bleeding, Thrombosis and Vascular Biology, 5(2). https://doi.org/10.4081/btvb.2026.467

Vancouver

Linari S, Pieri L, Pasquino R, Piellucci E, Attanasio M, Salvianti F, et al. Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors. Bleeding, Thrombosis and Vascular Biology. 2026;5(2). doi:10.4081/btvb.2026.467

BibTeX
@article{Linari2026,
  author = {Linari, Silvia and Pieri, Lisa and Pasquino, Raffaella and Piellucci, Eleonora and Attanasio, Monica and Salvianti, Francesca and Castaman, Giancarlo},
  title = {Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.4081/btvb.2026.467}
}
Kostenlos starten →